Having reiterated our Buy on weakness around the interims in March we are delighted with the share price performance since and the confirmation today that all three divisions had a good year. We will revisit our numbers and target price in due course but do not expect to change the former much at this stage. Having now exceeded our TP we will move back to Hold in the short term pending further analysis, but we remain fundamentally very positive on the Clinigen story with multiple growth opportu ....
18 Jul 2017
N+1 Singer - Clinigen Group - Fully year update reassuringly in line
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Clinigen Group - Fully year update reassuringly in line
- Published:
18 Jul 2017 -
Author:
Chris Glasper -
Pages:
3
Having reiterated our Buy on weakness around the interims in March we are delighted with the share price performance since and the confirmation today that all three divisions had a good year. We will revisit our numbers and target price in due course but do not expect to change the former much at this stage. Having now exceeded our TP we will move back to Hold in the short term pending further analysis, but we remain fundamentally very positive on the Clinigen story with multiple growth opportu ....